Galapagos NV Logo

Galapagos NV

Biotech firm developing novel CAR-T cell therapies for oncology via a rapid delivery platform.

GLPG | BR

Overview

Corporate Details

ISIN(s):
BE0003818359
LEI:
549300QKJ78IY0IOV655
Country:
Belgium
Address:
Industriepark Mechelen Noord, Generaal De Wittelaan L11 A3, 2800 Mechelen
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Galapagos NV is a biotechnology company dedicated to transforming patient outcomes through scientific innovation. Following a strategic restructuring, the company now focuses on developing and commercializing novel cell therapies, particularly in oncology. It leverages a unique, decentralized, and scalable manufacturing platform designed to rapidly deliver CAR-T therapies to patients. Galapagos is actively growing its pipeline through strategic acquisitions and partnerships while seeking to divest its legacy small molecule assets. The company's mission is to develop life-changing treatments to provide patients with more years of life and improved quality of life.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-26 07:30
Investor Presentation
GALAPAGOS_NV_Corp_Structure_TD_14.11.2025.pdf
German 151.3 KB
2025-11-26 07:30
Investor Presentation
GALAPAGOS_NV_Corp_Structure_TD_12.11.2025.pdf
German 151.9 KB
2025-11-26 07:30
Major Shareholding Notification
GALAPAGOS NV Form TD 14.11.2025_Revised Part I.pdf
English 956.3 KB
2025-11-26 07:30
Major Shareholding Notification
GALAPAGOS NV Form TD 12.11.2025_Part I_Revision2.pdf
English 956.0 KB
2025-11-26 07:30
Major Shareholding Notification
Galapagos Receives Transparency Notifications from Bank of America .pdf
English 243.9 KB
2025-11-26 07:30
Major Shareholding Notification
Galapagos ontvangt transparantieverklaringen van Bank of America .pdf
Dutch 283.4 KB
2025-11-05 22:01
Earnings Release
Galapagos Reports Nine Months 2025 Financial Results and Provides Business Upda…
English 465.4 KB
2025-11-05 22:01
Earnings Release
Galapagos rapporteert financiële resultaten over de eerste negen maanden van 20…
Dutch 593.4 KB
2025-10-21 07:30
Regulatory Filings
Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the…
English 274.0 KB
2025-10-21 07:30
Regulatory Filings
Galapagos kondigt intentie aan om celtherapieactiviteiten af te bouwen als onde…
Dutch 288.2 KB
2025-08-08 07:36
Share Issue/Capital Change
Galapagos Creates New Subscription Right Plan
Dutch 203.1 KB
2025-08-08 07:36
Share Issue/Capital Change
Galapagos Creates New Subscription Right Plan
English 201.6 KB
2025-08-07 00:00
Remuneration Information
Galapagos_PR_07082025_ENG.pdf
English 208.3 KB
2025-08-07 00:00
Remuneration Information
Galapagos_PR_07082025_NL.pdf
Dutch 215.6 KB
2025-08-07 00:00
Report Publication Announcement
1. Subscription Right Plan 2025 (B)_Board Report_7_180-7_191_ENG_FINAL_Website(…
English 262.4 KB

Automate Your Workflow. Get a real-time feed of all Galapagos NV filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Galapagos NV

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Galapagos NV via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-05-22 EcoR1 Capital Fund Qualified, L.P. Close relation Buy 58,375 1,681,760.40 USD
2025-05-22 EcoR1 Capital Fund, L.P. Close relation Buy 3,898 112,299.82 USD
2025-05-20 EcoR1 Capital Fund Qualified, L.P. Close relation Buy 14,321 412,553.64 USD
2025-05-20 EcoR1 Capital Fund, L.P. Close relation Buy 956 27,540.07 USD
2025-05-19 EcoR1 Capital Fund Qualified, L.P. Close relation Buy 9,376 261,151.60 USD
2025-05-19 EcoR1 Capital Fund, L.P. Close relation Buy 626 17,436.10 USD
2025-05-16 EcoR1 Capital Fund Qualified, L.P. Close relation Buy 39,112 1,077,934.54 USD
2025-05-16 EcoR1 Capital Fund, L.P. Close relation Buy 2,612 71,987.24 USD
2025-05-15 EcoR1 Capital Fund Qualified, L.P. Close relation Buy 187,480 5,015,090.00 USD
2025-05-15 EcoR1 Capital Fund, L.P. Close relation Buy 12,520 334,910.00 USD

Peer Companies

Mineralys Therapeutics, Inc. Logo
Developing targeted treatments for hypertension & CKD driven by elevated aldosterone.
United States of America
MLYS
Minerva Neurosciences, Inc. Logo
A clinical-stage biopharma developing treatments for central nervous system (CNS) diseases.
United States of America
NERV
MiNK Therapeutics, Inc. Logo
Developing allogeneic iNKT cell therapies for cancer and immune-mediated diseases.
United States of America
INKT
MIRA PHARMACEUTICALS, INC. Logo
Develops novel ketamine and THC analogs for neurologic and neuropsychiatric disorders.
United States of America
MIRA
Mirum Pharmaceuticals, Inc. Logo
Develops and commercializes therapies for rare, debilitating liver diseases in children and adults.
United States of America
MIRM
Mithra Pharmaceuticals S.A. Logo
Biotech firm developing pharma for women's health: contraception, fertility, and menopause.
Belgium
MITRA
MIZUHO MEDY CO.,LTD. Logo
Develops rapid diagnostic tests & gene analyzers for clinical, research & agricultural markets.
Japan
4595
MOA Life Plus Co. Ltd. Logo
Develops immunotherapies & consumer solutions for immunity, skin rejuvenation, and pet care.
South Korea
142760
Moberg Pharma Logo
Develops & commercializes a leading topical treatment for nail fungus for European markets.
Sweden
MOB
Mochida Pharmaceutical Co.,Ltd. Logo
An R&D-driven company making drugs, skincare, and medical equipment for specialized fields.
Japan
4534

Talk to a Data Expert

Have a question? We'll get back to you promptly.